Cantitate/Preț
Produs

Programmed Cell Death in Cancer Progression and Therapy: Advances in Experimental Medicine and Biology, cartea 615

Editat de Roya Khosravi-Far, Eileen White
en Limba Engleză Hardback – 7 ian 2008
Programmed cell death (PCD) plays pivotal roles in tumor progression, cancer therapeutics and resistance of tumor cells to therapy. With the discovery of key mechanisms that are involved in mediating PCD and in promoting resistance to therapy, design of therapeutic approaches for promoting tumor-selective cell death has risen dramatically. With this book, we give a comprehensive overview of the mechanisms that are involved in mediating and regulating PCD in cancer. We also provide a detailed indication of the utility of PCD in cancer therapy. This book will be a valuable resource for researchers investigating the role of PCD in cancer and other diseases, researchers investigating the molecular mechanism of chemotherapeutic agents and drug-resistance in cancer and for physicians using chemotherapeutic agents. Additionally, this book will be a important educational source for PhD students specializing in cell biology, immunology and MD students interested in Oncology and Cancer Therapeutics.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 130705 lei  38-44 zile
  SPRINGER NETHERLANDS – 25 noi 2010 130705 lei  38-44 zile
Hardback (1) 138396 lei  6-8 săpt.
  SPRINGER NETHERLANDS – 7 ian 2008 138396 lei  6-8 săpt.

Din seria Advances in Experimental Medicine and Biology

Preț: 138396 lei

Preț vechi: 145680 lei
-5% Nou

Puncte Express: 2076

Preț estimativ în valută:
26489 27608$ 22051£

Carte tipărită la comandă

Livrare economică 06-20 ianuarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9781402065538
ISBN-10: 1402065531
Pagini: 372
Ilustrații: XIV, 356 p.
Dimensiuni: 155 x 235 x 28 mm
Greutate: 0.79 kg
Ediția:2008
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Advances in Experimental Medicine and Biology

Locul publicării:Dordrecht, Netherlands

Public țintă

Research

Cuprins

Cell Death: History and Future.- Caspase Mechanisms.- The Mitochondrial Death Pathway.- Apoptotic Pathways in Tumor Progression and Therapy.- Therapeutic Targeting of Death Pathways in Cancer: Mechanisms for Activating Cell Death in Cancer Cells.- Overcoming Resistance to Apoptosis in Cancer Therapy.- Trail Receptors: Targets for Cancer Therapy.- Rational Design of Therapeutics Targeting the BCL-2 Family: Are Some Cancer Cells Primed for Death but Waiting for a Final Push?.- Autophagy and Tumor Suppression: Recent Advances in Understanding the Link between Autophagic Cell Death Pathways and Tumor Development.- Regulation of Programmed Cell Death by the P53 Pathway.- Regulation of Programmed Cell Death by NF-?B and its Role in Tumorigenesis and Therapy.- Targeting Proteasomes as Therapy in Multiple Myeloma.- Histone Deacetylase Inhibitors: Mechanisms and Clinical Significance in Cancer: HDAC Inhibitor-Induced Apoptosis.- RNA Interference and Cancer: Endogenous Pathways and Therapeutic Approaches.- Cancer Stem Cells and Impaired Apoptosis.

Recenzii

From the reviews:
"Programmed cell death (PCD) is an intriguing term that was introduced by Richard Lockshin nearly 45 years ago. … this book is about PCD with intense focus on apoptosis and the exploitation of PCD for treating cancer. … All chapters are well edited and thoroughly referenced. The nicety of the book is the use of numerous color figures. In my opinion, both scientists and clinicians, experienced or beginning, will profit from a thoughtful reading of Programmed Cell Death in Cancer Progression and Therapy." (A. A. Philchenkov, Biochemistry (Moscow), Vol. 74 (4), 2009)

Caracteristici

Up-to-date and comprehensive description of Molecular Mechanism of PCD in Cancer Progression and Therapy Up-to-date and comprehensive information regarding the current therapeutic strategies that utilize PCD Detailed indication of the utility of PCD in future cancer therapy Chapters on the current and future of RNA interference in therapeutics and Pathways involved in Stem Cell Survival and Death